POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement
Isotopia has developed a unique, stable, and reliable GMP method to produce a highly pure form of n.c.a.
- Isotopia has developed a unique, stable, and reliable GMP method to produce a highly pure form of n.c.a.
- Dr. Eli Shalom, CEO of Isotopia added, As Isotopia expands its manufacturing capabilities to secure supply for patients worldwide, we are always looking to partner with leaders in the radiopharmaceutical space and provide dependable support at all stages, clinical and commercial.
- About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. - Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com .